WO1990010448A3 - Conjugue covalent de lipides et d'oligonucleotides - Google Patents

Conjugue covalent de lipides et d'oligonucleotides Download PDF

Info

Publication number
WO1990010448A3
WO1990010448A3 PCT/US1990/001002 US9001002W WO9010448A3 WO 1990010448 A3 WO1990010448 A3 WO 1990010448A3 US 9001002 W US9001002 W US 9001002W WO 9010448 A3 WO9010448 A3 WO 9010448A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide
lipid
nucleotide sequence
conjugate
interest
Prior art date
Application number
PCT/US1990/001002
Other languages
English (en)
Other versions
WO1990010448A2 (fr
Inventor
Norbert W Bischofberger
Regan G Shea
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AT9090904028T priority Critical patent/ATE104857T1/de
Priority to DE69008521T priority patent/DE69008521T2/de
Priority to EP90904028A priority patent/EP0462145B1/fr
Publication of WO1990010448A2 publication Critical patent/WO1990010448A2/fr
Publication of WO1990010448A3 publication Critical patent/WO1990010448A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

Le conjugué décrit se compose d'un lipide qui est couplé de manière covalente à un oligonucléotide ayant une séquence de nucléotides qui, soit présente un intérêt, soit est sensiblement complémentaire à une séquence de nucléotides d'intérêt. Le conjugué est utile pour la purification d'acides nucléiques, des méthodes diagnostiques et des applications thérapeutiques. L'aspect thérapeutique comprend des conjugués dans lesquels l'oligonucléotide contient une séquence de nucléotides d'insensibilité contre une séquence codant un polypeptide responsable d'un trouble pathogénique.
PCT/US1990/001002 1989-03-07 1990-02-23 Conjugue covalent de lipides et d'oligonucleotides WO1990010448A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT9090904028T ATE104857T1 (de) 1989-03-07 1990-02-23 Kovalente konjugate von lipiden und oligonukleotiden.
DE69008521T DE69008521T2 (de) 1989-03-07 1990-02-23 Kovalente konjugate von lipiden und oligonukleotiden.
EP90904028A EP0462145B1 (fr) 1989-03-07 1990-02-23 Conjugue covalent de lipides et d'oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32020289A 1989-03-07 1989-03-07
US320,202 1989-03-07

Publications (2)

Publication Number Publication Date
WO1990010448A2 WO1990010448A2 (fr) 1990-09-20
WO1990010448A3 true WO1990010448A3 (fr) 1990-11-29

Family

ID=23245339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/001002 WO1990010448A2 (fr) 1989-03-07 1990-02-23 Conjugue covalent de lipides et d'oligonucleotides

Country Status (8)

Country Link
EP (1) EP0462145B1 (fr)
JP (1) JPH04503957A (fr)
AT (1) ATE104857T1 (fr)
CA (1) CA2049028A1 (fr)
DE (1) DE69008521T2 (fr)
DK (1) DK0462145T3 (fr)
ES (1) ES2055907T3 (fr)
WO (1) WO1990010448A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
DE69032847T2 (de) * 1989-06-30 1999-05-12 Chiron Corp Hydrophobe Nukleinsäure-Sonde
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US5852182A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals Inc. Thiol-derivatized oligonucleosides
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
AU652778B2 (en) * 1990-10-15 1994-09-08 Quest International B.V. Treatment composition
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
EP0575518A1 (fr) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Procedes et compositions d'inhibition selective de l'expression de genes
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US6831166B2 (en) 1992-10-23 2004-12-14 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
CA2134773A1 (fr) * 1992-06-04 1993-12-09 Robert J. Debs Methodes et compositions pour genotherapie in vivo
KR20030097604A (ko) * 1992-07-13 2003-12-31 유카리언, 인코포레이티드 세포의 세포내 구획으로 지질화된 면역글로불린을전달하기 위한 조성물, 지질화된 단백질 및 지질화된 항체
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
US5473060A (en) * 1993-07-02 1995-12-05 Lynx Therapeutics, Inc. Oligonucleotide clamps having diagnostic applications
US5571903A (en) * 1993-07-09 1996-11-05 Lynx Therapeutics, Inc. Auto-ligating oligonucleotide compounds
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
EP0888128A2 (fr) 1995-02-10 1999-01-07 The Worcester Foundation For Biomedical Research Apport de composes exogenes
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
ES2336857T3 (es) 1995-05-04 2010-04-16 Gilead Sciences, Inc. Complejos de ligandos de acido nucleico.
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5711964A (en) * 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6313106B1 (en) 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US5739271A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
US5851548A (en) * 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
WO1996040627A2 (fr) * 1995-06-07 1996-12-19 Gen-Probe Incorporated Lipides thiocationiques, preparations pharmaceutiques et leurs modes d'utilisation
US5756352A (en) * 1995-06-07 1998-05-26 Gen-Probe Incorporated Thiocationic lipid-nucleic acid conjugates
US5759519A (en) * 1995-06-07 1998-06-02 Gen-Probe Incorporated Method for the intracellular delivery of biomolecules using thiocationic lipids
AU6266896A (en) * 1995-06-07 1996-12-30 Eukarion, Inc. Transvacular and intracellular delivery of lipidized protein s
KR101004174B1 (ko) 1995-06-29 2010-12-24 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
JPH11511128A (ja) * 1995-08-01 1999-09-28 ノバルティス・アクチエンゲゼルシャフト リポソームオリゴヌクレオチド組成物
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
EP0923596A2 (fr) * 1996-07-31 1999-06-23 Gilead Sciences, Inc. Analogues lipophiles d'oligonucleotides
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
PT957929E (pt) * 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
EP1865061A3 (fr) 1998-05-15 2007-12-19 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP3112468A1 (fr) 1998-05-15 2017-01-04 Genentech, Inc. Polypeptides allogéniques il-17 et utilisations thérapeutiques
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DK1105485T3 (da) 1998-08-21 2006-10-30 Immunex Corp Human IL-1-epsilon-DNA og polypeptider
US6248553B1 (en) 1998-10-22 2001-06-19 Atairgin Technologies, Inc. Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
CA2368385C (fr) 1999-03-26 2012-05-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Gene prostatique specifique, famille de genes pcgem1, et methodes d'emploi de pcgem1 pour la detection, le traitement et la prevention du cancer de la prostate
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
ES2251134T3 (es) * 1999-06-08 2006-04-16 Gentium S.P.A. Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos.
EP1978029A3 (fr) 1999-06-15 2008-10-15 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
AU1095001A (en) 1999-10-20 2001-04-30 Genentech Inc. Type i cytokine receptor tccr
CA2492070A1 (fr) 1999-12-01 2001-06-07 Kevin P. Baker Polypeptides pro4329 marqueurs de tumeurs du poumon et acides nucleiques codant lesdits polypeptides
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
CA2403809A1 (fr) 2000-03-22 2001-09-27 Curagen Corporation Proteines associees a l'angiogenese et acides nucleiques codant ces proteines
KR100352171B1 (ko) * 2000-04-14 2002-09-12 (주) 제노텍 올리고뉴클레오타이드를 지지체에 고정시키는 방법 및 그방법에 의하여 제조되는 올리고뉴클레오타이드 어레이
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
EP2014298A3 (fr) 2000-08-24 2009-10-07 Genentech, Inc. Polypeptides d'interleukine-22, acides nucléiques les codant et procédés de traitement des troubles pancréatiques
EP1944317A3 (fr) 2000-09-01 2008-09-17 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030232334A1 (en) 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP2000545B1 (fr) 2001-06-20 2011-08-31 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur pulmonaire
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
KR100623128B1 (ko) 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
ATE431406T1 (de) 2002-02-25 2009-05-15 Genentech Inc Neuer typ-1-cytokinrezeptor glm-r
EP2093233A1 (fr) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Nouvelles compositions et nouveaux procédés pour le cancer
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2004016733A2 (fr) 2002-08-16 2004-02-26 Agensys, Inc. Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers
CA2860151A1 (fr) 2003-02-10 2004-08-26 Agensys, Inc. Acide nucleique et proteine correspondante dite 158p1d7, utiles pour le traitement et la detection de cancers de la vessie et autres
WO2004074321A2 (fr) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Nouveaux cibles therapeutiques du recepteur de couplage a la proteine g dans le cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
CN101090729B (zh) 2003-05-30 2014-07-23 艾更斯司股份有限公司 前列腺干细胞抗原(psca)变体及其序列
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
EP1667522B1 (fr) 2003-09-09 2018-01-17 Geron Corporation Oligonucléotides modifiés destinés à l'inhibition de la télomérase
SI2161283T1 (sl) 2003-11-17 2014-10-30 Genentech, Inc. Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
US7323551B2 (en) 2004-01-27 2008-01-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibiting squamous cell carcinoma
US7875277B2 (en) 2004-01-27 2011-01-25 The Dept. of Veterans Affairs Office of The General Counsel Compositions and methods for inhibiting squamous cell carcinoma
AU2005250370B2 (en) 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
CA2597325A1 (fr) 2005-03-10 2006-09-21 Genentech, Inc. Procedes et compositions de modulation de l'integrite vasculaire
WO2006105488A2 (fr) 2005-03-31 2006-10-05 Agensys, Inc. Anticorps et molecules correspondantes qui se fixent aux proteines 161p2f10b
EP1865981A2 (fr) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e dans le diagnostic, la detection et le traitement du cancer
WO2006110581A2 (fr) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Genes associes au cancer
WO2006132788A2 (fr) 2005-06-06 2006-12-14 Genentech, Inc. Nouvelles disruptions geniques, nouvelles compositions et nouveaux procedes s'y rapportant
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
EP2050335A1 (fr) 2006-02-17 2009-04-22 Genentech, Inc. Dislocation de gènes, compositions et procédés correspondants
EP2007428A2 (fr) 2006-04-05 2008-12-31 Genentech, Inc. Méthode d'utilisation du boc/cdo pour moduler l'émission des signaux du hedgehog
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US8263403B2 (en) 2007-04-23 2012-09-11 Stowers Institute For Medical Research Methods and compositions for stem cell self-renewal
AR068332A1 (es) 2007-08-03 2009-11-11 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
EP2105145A1 (fr) * 2008-03-27 2009-09-30 ETH Zürich Procédé pour la libération spécifique dans les muscles d'oligonucléotides conjugués avec des lipides
EP2328908A4 (fr) 2008-08-28 2012-11-28 Univ New York State Res Found Traitement des amyloïdoses au moyen de protéines basiques de myéline ou de fragments desdites
US20100183620A1 (en) 2008-11-26 2010-07-22 Kaumudi Bhawe Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
CN102656266B (zh) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
MX2012006072A (es) 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
EP2625197B1 (fr) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened et ses procédés d'utilisation
EP2781523A1 (fr) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Analogues oligonucléotides lipophiles
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
AU2015214264B2 (en) 2014-02-04 2018-12-20 Curis, Inc. Mutant Smoothened and methods of using the same
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
WO2018152327A1 (fr) * 2017-02-15 2018-08-23 Northwestern University Amélioration de la stabilité et de l'activité immunomodulatrice d'acides nucléiques sphériques liposomaux
KR20210018267A (ko) 2018-05-07 2021-02-17 알닐람 파마슈티칼스 인코포레이티드 간외 전달

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3637243A1 (de) * 1985-11-02 1987-05-07 Toa Gosei Chem Ind Neue phosphorsulfidderivate von deoxynucleosiden oder deoxynucleotiden und deren verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3637243A1 (de) * 1985-11-02 1987-05-07 Toa Gosei Chem Ind Neue phosphorsulfidderivate von deoxynucleosiden oder deoxynucleotiden und deren verwendung

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biotechniques, Vol. 6, No. 10, 1988, A.R. VAN DER KROL et al.: "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences", pages 958-974 *
Chemical Reviews, Vol. 90, No. 4, June 1990, American Chemical Society, E. UHLMANN et al.: "Antisense Oligonucleotides: a New Therapeutic Principle", pages 556-562 & Human Retroviruses, Cancer and Aids, Approaches to Prevention and Therapy, (GOODCHILD et al.) 1988, New York, page 423 *
Nucleid Acids Research, Vol. 15, No. 14, 1987, IRL Press Ltd, (Oxford, GB), C.J. MARCUS-SEKURA et al.: "Comparative Inhibition of Chloramphenicol Acetyltransferase Gene Expression by Antisense Oligonucleotide Analogues having Alkyl Pholsphotriester, Methylphosphonate and Phosphorothioate Linkages", pages 5749-5763 *
Proc. Natl. Acad. Sci. USA, Vol. 86, September 1989, R.L. LETSINGER et al.: "Cholesterylconjugated Oligonucleotides: Synthesis, Properties, and Activity as Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture", pages 6553-6556 *
STN File Server (Karlsruhe) & File CA, CHEMICAL ABSTRACTS, Vol. 109, 1988, (Columbus, Ohio, US), E.E. BICHENKOV et al.: "Interaction of Cholesterol-Modified Polynucleotide with Phosphatidylcholine Liposomes", see Abstract 225156z, & Biol. Membr., 5(7), 735-42 *
STN File Server (Karlsruhe) & File Medline, H. YANAGAWA et al.: "Analysis of Superhelical Structures of Nucleid Acidlipid Conjugates by Image Processing", see Accession Number 89144950, & Nucleid Acids Symp. Ser., (1988), (19), 189-92 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

Also Published As

Publication number Publication date
CA2049028A1 (fr) 1990-09-08
DE69008521D1 (de) 1994-06-01
JPH04503957A (ja) 1992-07-16
EP0462145B1 (fr) 1994-04-27
DK0462145T3 (da) 1994-08-08
DE69008521T2 (de) 1994-10-20
ATE104857T1 (de) 1994-05-15
EP0462145A1 (fr) 1991-12-27
ES2055907T3 (es) 1994-09-01
WO1990010448A2 (fr) 1990-09-20

Similar Documents

Publication Publication Date Title
WO1990010448A3 (fr) Conjugue covalent de lipides et d'oligonucleotides
NZ289720A (en) Nucleic acids coding for a telomerase, a ribonucleoprotein enzyme involved in telomere synthesis
EP0396116A3 (fr) Fixation covalente des membres de liaison spécifiques aux phases solides
AU1525588A (en) Improved dna probes
WO1996001614A3 (fr) Composant d'arn de la telomerase
AU5001496A (en) Introduction of dna into bacillus strains by conjugation
BR9812381A (pt) Peptopiranosilnucleosìdeo, seu preparo e uso
EP0383803A4 (en) Oligonucleotide-polyamide conjugates
WO1995013095A3 (fr) Therapie
AU6006198A (en) Process for the preparation of caprolactam in the absence of catalysts by contacting 6-aminocaproic acid derivatives with superheated steam
AU2366988A (en) Process for the preparation of functionalized polymers
AU4897096A (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
BR9105533A (pt) Processo de preparacao de catalisadores revestidos,do tipo molibdatos de bismuto e de ferro,dopados principalmente com fosforo e potassio
EP0689460A4 (fr) Oligonucleotides anti-sens contenant des cycles cyclobutyle, leurs procedes de preparation et d'utilisation
FR2604438B1 (fr) Nouveaux conjugues de couplage entre des sequences d'arn ou d'adn et une proteine, leur procede de preparation et leur application biologique
AU8896091A (en) Labelled, modified oligonucleotides
WO1996015240A3 (fr) Analogues de ribozymes
CA2066263A1 (fr) Recepteur de thyrotropine
EP1108786A4 (fr) Nouvelle collectine
AU2599788A (en) Polyketone polymer preparation
AU1164588A (en) Nucleotide analogs, their production and use
EP0283948A3 (en) Polymers modified by acid end groups, their manufacture and their use
AU2455088A (en) Polyketone polymers
AU1373197A (en) Covalent lipid-phosphonocarboxylic acid conjugates, the production thereof as well as their use as antiviral pharmaceutical agents
AU2321888A (en) Specific dna molecular probes for bos-type male genome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990904028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2049028

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1990904028

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990904028

Country of ref document: EP

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2049028

Kind code of ref document: A

Format of ref document f/p: F